CorMedix
CRMD
62 hedge funds and large institutions have $46.9M invested in CorMedix in 2019 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 27 increasing their positions, 9 reducing their positions, and 7 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 9
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
14% more capital invested
Capital invested by funds: $41.3M → $46.9M (+$5.58M)
11% more funds holding
Funds holding: 56 → 62 (+6)
0.73% less ownership
Funds ownership: 25.84% → 25.11% (-0.73%)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
86% less call options, than puts
Call options by funds: $204K | Put options by funds: $1.43M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$655K |
| 2 |
Nuveen
Charlotte,
North Carolina
|
+$612K |
| 3 |
Renaissance Technologies
New York
|
+$345K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$283K |
| 5 |
D.E. Shaw & Co
New York
|
+$185K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.59M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$1.46M |
| 3 |
VF
Virtu Financial
New York
|
-$302K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$254K |
| 5 |
Millennium Management
New York
|
-$161K |
CRMD Hedge Fund Activity: Q4 2019 in Review
62 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q4 2019, worth a combined $46.9M — up 14% from $41.3M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new CRMD positions and 7 closed out — a net gain of 6 holders — while 27 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $655K. The largest seller was Sabby Management, exiting entirely with an estimated $1.59M sold.
- 62 institutional investors held CorMedix (CRMD) as of Q4 2019, up from 56 in Q3 2019.
- Funds reported $46.9M of CorMedix stock for Q4 2019, up 14% quarter-over-quarter.
- 13 funds opened new CorMedix positions in Q4 2019 and 7 closed out, a net change of +6 holders.
- The largest CorMedix buyer in Q4 2019 was BlackRock, an estimated $655K added.
- The largest CorMedix seller in Q4 2019 was Sabby Management, an estimated $1.59M sold.
Based on aggregated 13F filings for Q4 2019.